That Other Biotech Patent Interference – Forbes
|
That Other Biotech Patent Interference
Forbes As has been written about—at length—elsewhere, much of the biotech world awaits the outcome of a patent dispute over CRISPR, a revolutionary form of gene-editing biotechnology worth many billions of dollars. Unlike a typical patent dispute in federal … |
